[removed]Kamada[/removed], Ness Ziona, Israel, a biopharmaceutical company, announced that interim results of its phase 2-3 trial of inhaled alpha-1 antitrypsin (AAT) show a good safety and tolerability profile for the product. According to the company, the report, which includes information on 13 months of treatment of dozens of patients, further adds to the safety profile of inhaled AAT established in five previous clinical trials completed by the company.
The current phase 2-3 trial is the most advanced stage a company has ever reached with inhaled AAT. The trial is being conducted at several sites in Europe, including Germany, the United Kingdom, the Netherlands, Denmark, Ireland, and Scotland.
Inhaled AAT is delivered via the investigational eFlow nebulizer system developed by PARI Pharma GmbH and has been designated orphan drug for the treatment of bronchiectasis, alpha-1 deficiency, and cystic fibrosis in the United States.
“These results are encouraging not only to alpha-1 patients but also to other patients who suffer from chronic respiratory diseases such as cystic fibrosis, bronchiectasis, and COPD and for whom AAT by inhalation could be a treatment option,” says David Tsur, chief executive officer of Kamada.